文献速递血栓与止血

主动性系统性血友病携带者筛查:迈向血友病诊疗中的性别公平

Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care.
PubMed 文献 · Blood Adv · 2024-01-01

在比利时布鲁塞尔圣吕克大学医院,通过更新所有血友病患者家系图识别潜在和必然携带者,并向未筛查或筛查不完整的个体发送125封邀请信。共识别900名女性个体,其中454名为必然和/或基因证实携带者;在已知因子水平的携带者中,23.0%的HA携带者和29.5%的HB携带者因子水平低于40 IU/dL。

要点

  • 共识别454名必然和/或基因证实携带者,其中190名必然携带者和328名潜在携带者仍未检测。
  • 已知因子水平的携带者中,42名HA携带者(23.0%)和23名HB携带者(29.5%)因子水平低于40 IU/dL。
  • 因子缺乏的携带者比其他女性平均早筛查6年(P = .034)。

核心结论

  • 本研究为据作者所知首次在单中心对所有血友病患者家系进行系统性潜在携带者识别,凸显了对与一名或多名血友病患者有遗传关联的女性个体进行全面筛查的挑战。
  • 此类举措对于实现所有可能受影响个体不论性别均能公平获得血友病诊疗至关重要。

研究设计与样本

  • 研究于2021年5月至2023年4月在布鲁塞尔圣吕克大学医院进行,通过更新所有随访血友病患者的家系图识别A型血友病(HA)和B型血友病(HB)的潜在和必然携带者。
  • 回顾性收集既往已筛查女性的出血史、凝血因子水平和先证者致病性变异检测数据;同时通过相关血友病患者向未筛查或筛查不完整的个体发送125封邀请信进行主动性筛查。
  • 在287名男性血友病患者(226例HA和61例HB)和7名女性索引患者(来自236个家系:184个HA家系和52个HB家系)的家系中,共识别900名女性个体。

主要发现

  • 900名女性个体中,454名为必然和/或基因证实携带者,118名为非携带者。
  • 基因检测在133名必然携带者、237名潜在携带者和4名散发性携带者中进行;190名必然携带者和328名潜在携带者仍未检测。
  • 在已知因子水平的携带者(261/454)中,42名HA携带者(23.0%)和23名HB携带者(29.5%)的因子水平低于40 IU/dL。
  • 因子缺乏的携带者比其他女性平均早筛查6年(P = .034)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite numerous efforts to raise awareness, many hemophilia carriers and female persons with hemophilia (PWHs) remain undiagnosed. Between May 2021 and April 2023, we identified potential and obligate carriers of hemophilia A (HA) and hemophilia B (HB) by updating pedigrees of all PWHs followed at the Cliniques universitaires Saint-Luc, Brussels. Retrospective data on previously screened females were collected, including bleeding history, coagulation factor levels, and testing for the proband's pathogenic variant. In addition, a proactive approach involved sending 125 invitation letters to unscreened or incompletely screened individuals, through related PWHs. In pedigrees of 287 male PWHs (226 HA and 61 HB) and 7 female index patients from 236 families (184 HA and 52 HB), a total of 900 female individuals were identified. Of those, 454 were obligate and/or genetically proven carriers, and 118 were noncarriers. Genetic testing was conducted in 133 obligate, 237 potential, and 4 sporadic carriers, with 190 obligate and 328 potential carriers remaining untested. Among carriers with known factor levels (261/454), 42 HA (23.0%) and 23 HB carriers (29.5%) had a factor level <40 IU/dL. Carriers with a factor deficiency were screened on average 6 years earlier than other females (P = .034). This study, to our knowledge, represents the first systematic effort to identify potential carriers among families of all PWHs within a single center, emphasizing the challenges in comprehensive screening for female individuals genetically linked to one or more PWHs. Such initiatives are vital for achieving equitable access to hemophilia care for all potentially affected individuals, irrespective of gender. This trial was registered at www.ClinicalTrials.gov as #NCT05217992.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Krumb E, Lambert C, Van Damme A, et al. Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care. Blood Adv. 2024. PMID: 39167764. doi:10.1182/bloodadvances.2024013866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。